The urgent, shared global race to develop an effective vaccine for the novel coronavirus (Covid-19) dramatically illustrates how the unexpected onset and rapid spread of an infectious disease can upend established biopharmaceutical R&D processes, timetables, and collaborations. It also increases conjecture about other existing and/or emerging forces that may disrupt the Biopharma Business industry identification, […]
